Recent Update of Renin-Angiotensin-Aldosterone System in the Pathogenesis of Hypertension
doi:10.36849/JDD.6550 INTRODUCTION Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition
Kidney Blood Press Res (2019) 44(4):44956
TEXT ON-SCREEN: Debe cambiar (alternar) el lugar de inyeccin con cada inyeccin
The safety profile of semaglutide is similar to other GLP-1 agonists
DOI: Published online: May 1, 2025 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea 2 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea Corresponding author: Jae Hyun Bae Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea E-mail: [email protected] Copyright 2025 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
